Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Boundless Bio, Inc. is a clinical-stage biotechnology company focused on developing novel cancer therapeutics that target extrachromosomal DNA (ecDNA), a genetic mechanism implicated in oncogene amplification, tumor progression, and drug resistance. The company operates within the biotechnology and oncology therapeutics industries, with a strategic emphasis on cancers driven by ecDNA across solid tumors.
The company’s primary value proposition centers on its ecDNA-directed therapeutic platform, which is designed to identify and drug vulnerabilities unique to ecDNA biology. Boundless Bio’s pipeline is anchored by internally discovered small-molecule drug candidates targeting transcriptional and replication processes associated with ecDNA. Founded in 2018 and publicly listed on NASDAQ in 2023, the company emerged from academic research conducted at the University of California, San Diego, and has evolved into a standalone clinical-stage enterprise advancing first-in-class oncology programs.
Business Operations
Boundless Bio operates as a single-reportable-segment biotechnology company, generating no commercial revenue to date and focusing primarily on research and development activities. Its operations are centered on the discovery, preclinical development, and clinical advancement of ecDNA-targeted cancer therapies, with expenditures primarily related to R&D, clinical trials, and platform development.
The company’s core assets include its proprietary ecDNA mapping and analytical technologies, which are used to identify actionable targets and guide drug development. Lead product candidates include BBI-355 and BBI-825, both of which are designed to disrupt ecDNA-driven oncogenic processes. As of the most recent public disclosures, Boundless Bio does not report material revenue-generating partnerships and conducts most research internally, supplemented by contract research organizations and academic collaborations. No material subsidiaries or joint ventures have been publicly disclosed.
Strategic Position & Investments
Strategically, Boundless Bio is positioned as a pioneer in the emerging field of ecDNA-directed oncology, aiming to establish a new therapeutic category distinct from traditional precision oncology approaches. Its growth strategy focuses on advancing its lead programs through early-stage clinical development while expanding its discovery pipeline through continued investment in ecDNA biology and drug discovery capabilities.
The company has not disclosed any major acquisitions since inception and remains primarily organically grown. Investment activity has largely been directed toward internal R&D, clinical trial execution, and platform enhancement. Boundless Bio’s intellectual property portfolio and scientific leadership in ecDNA research are viewed as key strategic assets, although long-term clinical and commercial validation remains in development. Data inconclusive based on available public sources regarding material equity investments or portfolio companies beyond its core operations.
Geographic Footprint
Boundless Bio is headquartered in San Diego, California, which serves as the center of its research, development, and corporate operations. The company’s activities are predominantly based in the United States, with no material international offices reported in public filings.
While clinical trials may involve investigational sites outside the U.S., the company does not currently report significant international operational infrastructure. Its global footprint is therefore limited, with international engagement primarily occurring through clinical research activities and scientific collaboration rather than direct commercial or manufacturing presence.
Leadership & Governance
Boundless Bio was co-founded by Zachary Smith, who has played a central role in shaping the company’s scientific and strategic direction. The leadership team combines expertise in oncology drug development, translational science, and biotechnology company building, with a stated focus on rigorous science and first-in-class therapeutic innovation.
Key executives include:
- Zachary Smith – Chief Executive Officer
- Trevor McFarland – Chief Scientific Officer
- Perry Nisen – President (role and scope based on public disclosures; title details vary across sources)
The board and executive leadership emphasize long-term value creation through scientific differentiation, disciplined capital deployment, and advancement of novel cancer therapies. Certain executive role definitions show minor variation across public sources; where discrepancies exist, data inconclusive based on available public sources.